Abstract Details

Title Serum Biomarker Profile in Multiple Sclerosis Treated with Autologous Bone Marrow Transplant

Topic Multiple Sclerosis

Presentation(s) P5 - Poster Session 5 (8:00 AM-9:00 AM)

Poster/Presentation
Number 1-012

Objective We examined dynamics of serum biomarker profile in patients with multiple sclerosis (MS) following autologous bone marrow transplant (aHSCT).

Background Several studies have demonstrated efficacy of autologous bone marrow transplant in treatment of multiple sclerosis. The use of this treatment modality is currently limited pending results of larger a randomized controlled trial and FDA approval. However, as a measure of last resort in select MS patients, this treatment is offered at some institutions. No studies have examined serum biomarker profile dynamics in patients receiving aHSCT.

Design/Methods We have collected Octave Biosciences Inc Multiple Sclerosis Disease Activity panel (Octave MSDA) in 13 patients with MS who underwent aHSCT at UCI and maintained disease stability. 6 patients had longitudinal testing during the first year after aHSCT. Clinical, imaging and laboratory data was retrospectively collected. Data was analyzed using R.

Results Age-adjusted serum biomarker levels fluctuated from baseline during first year post-treatment. We found that biomarkers of neuroaxonal damage to be elevated shortly after aHSCT and then normalize within 6-12 months. Long-term elevation of B-cell activating factor (BAFF) was observed in all patients likely due to use of B-cell depleting agents either prior to aHSCT or as part of the myeloablative protocol. We also report several correlations between serum biomarker profile and symptomatic status of patients following aHSCT.

Conclusions Serum biomarker profile can be considered as an objective and dynamic measure to monitor MS patients after aHSCT.

Authors/Disclosures
Arina Alexeeva, MD PRESENTER	Dr. Alexeeva has nothing to disclose.
Anastasia Chumakova, MD (UCI Medical Center)	Dr. Chumakova has nothing to disclose.
Michael Demetriou, MD, PhD	Dr. Demetriou has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Demetriou has stock in GlyTR Therapeutics. Dr. Demetriou has received intellectual property interests from a discovery or technology relating to health care.
Michael Y. Sy, MD, PhD (University of California, Irvine)	Dr. Sy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Sy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Bioscience. Dr. Sy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Sy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Sy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Sy has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Sy has received intellectual property interests from a discovery or technology relating to health care.
Gaby T. Thai, MD, FAAN (UC Irvine)	Dr. Thai has nothing to disclose.

��ɫ��

��ɫ��